Inactive Instrument

Press Releases Peregrine Pharmaceuticals Nasdaq

Equities

US7136615025

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

Avid Bioservices: Fiscal Q3 Earnings Snapshot	Apr. 24	AQ
Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2024	Apr. 24	AQ
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Avid Bioservices, Inc. - CDMO	Apr. 12	PR
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Avid Bioservices, Inc. - CDMO	Apr. 04	PR
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Avid Bioservices, Inc. - CDMO	Mar. 27	PR
Avid Bioservices Announces Receipt of Deficiency Notice from Nasdaq Regarding Late Form 10-Q	Mar. 20	AQ
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Avid Bioservices, Inc. (CDMO) on Behalf of Investors	Mar. 14	BU
Avid Bioservices, Inc. (CDMO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings	Mar. 14	BU
Law Offices of Howard G. Smith Announces Investigation of Avid Bioservices, Inc. (CDMO) on Behalf of Investors	Mar. 13	BU
The Law Offices of Frank R. Cruz Announces Investigation of Avid Bioservices, Inc. (CDMO) on Behalf of Investors	Mar. 13	BU
Avid Bioservices, Inc. (CDMO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings	Mar. 07	BU
CDMO LOSS ALERT: ROSEN, A LEADING LAW FIRM, Encourages Avid Bioservices, Inc. Investors to Inquire About Securities Class Action Investigation – CDMO	Mar. 07	BU
Avid Bioservices Announces Pricing of Private Placement of Convertible Notes	Mar. 06	AQ
Avid Bioservices Announces Proposed Private Placement of Convertible Notes	Mar. 06	AQ
Avid Bioservices Announces Certain Preliminary Financial Results for Third Quarter Ended January 31, 2024	Mar. 06	AQ
Avid Bioservices: Fiscal Q2 Earnings Snapshot	Dec. 07	AQ
Avid Bioservices Reports Financial Results for Second Quarter Ended October 31, 2023	Dec. 07	AQ
Avid Bioservices to Report Financial Results for Second Quarter of Fiscal Year 2024 After Market Close on December 7, 2023	Nov. 30	AQ
Avid Bioservices Partners with California Institute for Regenerative Medicine to Provide CDMO Services for Cell and Gene Therapy Programs	Nov. 09	AQ
Avid Bioservices Partners With California Institute for Regenerative Medicine (CIRM) to Provide CDMO Services for Cell and Gene Therapy (CGT) Programs	Nov. 08	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Peregrine Pharmaceuticals Nasdaq

Equities

US7136615025

Press Releases

Filters